These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9280665)

  • 21. Impact of pramipexole on the onset of levodopa-related dyskinesias.
    Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K;
    Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is levodopa toxic to human substantia nigra?
    Riley D
    Mov Disord; 1998 Mar; 13(2):369-70. PubMed ID: 9539360
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurological motor disorders experienced as religious phenomena: role of abnormal movement monitoring.
    Lauerma H; Tuliharju M
    Brain Cogn; 1998 Feb; 36(1):52-6. PubMed ID: 9500883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frégoli syndrome associated with levodopa treatment.
    Stewart JT
    Mov Disord; 2008 Jan; 23(2):308-9. PubMed ID: 18044770
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of levodopa-induced dyskinesias with donepezil.
    Caroff SN; Martine R; Kleiner-Fisman G; Eisa M; Lorry A; Gallop R; Stern MB; Duda JE
    Parkinsonism Relat Disord; 2006 May; 12(4):261-3. PubMed ID: 16364675
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of levodopa failure syndrome by posteroventral-ansa pallidotomy.
    Iacono RP; Carlson JD; Mohamed AS; Kuniyoshi SM
    Adv Neurol; 1999; 80():619-22. PubMed ID: 10410779
    [No Abstract]   [Full Text] [Related]  

  • 29. Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
    Růzicka E; Urgosík D; Jech R; Roth J; Vymazal J; Mecír P; Vladyka V
    Mov Disord; 2005 Jun; 20(6):759-62. PubMed ID: 15782419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Sunohara N
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):527-31. PubMed ID: 10434715
    [No Abstract]   [Full Text] [Related]  

  • 31. [Motor complications of treatment with levodopa in Parkinson's disease].
    García-Escrig M; Bermejo-Pareja F
    Rev Neurol; 1999 Apr 16-30; 28(8):799-809. PubMed ID: 10363326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Apraxia of eyelid opening" induced by levodopa therapy and apomorphine in atypical parkinsonism (possible progressive supranuclear palsy): a case report.
    Defazio G; De Mari M; De Salvia R; Lamberti P; Giorelli M; Livrea P
    Clin Neuropharmacol; 1999; 22(5):292-4. PubMed ID: 10516881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG
    Mov Disord; 2008; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
    Aubert I; Guigoni C; Li Q; Dovero S; Bioulac BH; Gross CE; Crossman AR; Bloch B; Bezard E
    Biol Psychiatry; 2007 Apr; 61(7):836-44. PubMed ID: 16950226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hypersexuality during use of levodopa].
    van Puijenbroek EP; Diemont WL
    Ned Tijdschr Geneeskd; 2003 May; 147(20):990. PubMed ID: 12784535
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.